[EN] COMPOUNDS FOR THE TREATMENT OF PREMATURE EJACULATION<br/>[FR] COMPOSES PERMETTANT DE TRAITER L'EJACULATION PRECOCE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2004026237A2
公开(公告)日:2004-04-01
The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds [INSERT CHEMICAL STRUCTURE HERE] (I) useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.
Compounds for the treatment of premature ejaculation
申请人:——
公开号:US20040063768A1
公开(公告)日:2004-04-01
The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds
1
useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.
Conformationally restricted homotryptamines. Part 5: 3-(trans-2-aminomethylcyclopentyl)indoles as potent selective serotonin reuptake inhibitors
作者:Derek J. Denhart、Jeffrey A. Deskus、Jonathan L. Ditta、Qi Gao、H. Dalton King、Edward S. Kozlowski、Zhaoxing Meng、Melissa A. LaPaglia、Gail K. Mattson、Thaddeus F. Molski、Matthew T. Taber、Nicholas J. Lodge、Ronald J. Mattson、John E. Macor
DOI:10.1016/j.bmcl.2009.06.026
日期:2009.8
A series of racemic 3-(trans-2-aminomethylcyclopentyl)indoles was synthesized and found to have potent binding to the human serotonin transporter (hSERT). The most active analog was synthesized stereospecifically and the active enantiomer was shown to have high affinity binding to hSERT. (C) 2009 Elsevier Ltd. All rights reserved.